Shares of Vascular Biogenics Ltd. (NASDAQ:VBLT) have received an average rating of “Hold” from the six brokerages that are covering the firm, MarketBeat Ratings reports. Two analysts have rated the stock with a sell rating and four have assigned a buy rating to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $14.75.

Several brokerages have recently weighed in on VBLT. ValuEngine cut shares of Vascular Biogenics from a “hold” rating to a “sell” rating in a research note on Tuesday, June 6th. Zacks Investment Research cut shares of Vascular Biogenics from a “hold” rating to a “sell” rating in a research note on Friday, August 18th. Finally, HC Wainwright set a $11.00 price objective on shares of Vascular Biogenics and gave the stock a “buy” rating in a research note on Tuesday, August 15th.

Vascular Biogenics (VBLT) remained flat at $5.25 during mid-day trading on Friday. 80,610 shares of the company traded hands. Vascular Biogenics has a one year low of $3.90 and a one year high of $6.70. The stock’s market cap is $141.80 million. The firm has a 50-day moving average of $4.80 and a 200 day moving average of $5.16.

Vascular Biogenics (NASDAQ:VBLT) last issued its quarterly earnings data on Monday, August 14th. The biopharmaceutical company reported ($0.18) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.19) by $0.01. Equities research analysts expect that Vascular Biogenics will post ($0.74) EPS for the current year.

An institutional investor recently bought a new position in Vascular Biogenics stock. KCG Holdings Inc. acquired a new position in Vascular Biogenics Ltd. (NASDAQ:VBLT) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 45,106 shares of the biopharmaceutical company’s stock, valued at approximately $248,000. KCG Holdings Inc. owned 0.17% of Vascular Biogenics as of its most recent SEC filing. Institutional investors and hedge funds own 11.28% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Vascular Biogenics Ltd. (VBLT) Given Consensus Recommendation of “Hold” by Brokerages” was originally reported by American Banking News and is the property of of American Banking News. If you are reading this article on another website, it was copied illegally and republished in violation of U.S. and international copyright legislation. The original version of this article can be accessed at https://www.americanbankingnews.com/2017/09/16/vascular-biogenics-ltd-vblt-given-consensus-recommendation-of-hold-by-brokerages.html.

Vascular Biogenics Company Profile

Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of treatments for cancer. The Company’s program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels.

Receive News & Ratings for Vascular Biogenics Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.